Talking for Change: Secondary Prevention of Child Sexual Abuse Perpetration
Launched by CENTRE FOR ADDICTION AND MENTAL HEALTH · May 23, 2025
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
The "Talking for Change" trial is a research study aimed at preventing child sexual abuse by testing a special therapy program called Talking for Change (TFC). This study is looking at how effective the TFC program is in reducing the risk of someone committing sexual offenses against children. Participants in the study will be divided into three groups: one will receive the TFC therapy for 20 weeks, another will receive a different kind of therapy that focuses on general mental health and stress, and the third group will not receive any treatment at all. Researchers will assess changes in behaviors and thoughts related to child sexual abuse through interviews and self-reports.
To participate in this study, individuals must be male, at least 18 years old, and have been referred for help due to concerns about their risk of offending against children. They also need to be able to understand and agree to the study's requirements. However, those with certain conditions that make it hard to participate meaningfully, or those who do not identify as male, will not be eligible. Participants can expect to engage in group discussions and therapy sessions designed to help them manage their thoughts and behaviors more effectively. This trial is currently in the recruiting phase, welcoming individuals who meet the eligibility criteria.
Gender
MALE
Eligibility criteria
- INCLUSION CRITERIA:
- For the treatment arms, the participant must meet all of the inclusion criteria to eligible for this clinical trial:
- • 1. Must be deemed to have capacity to provide informed consent;
- • 2. Must sign and date the informed consent form;
- • 3. Stated willingness to comply with all study procedures;
- • 4. Be 18 years of age or older upon study commencement;
- • 5. Be referred for care in the TFC program due to concerns about enhanced risk of sexual offending against children.
- For the benchmarking interview arm, the participant must meet all of the following inclusion criteria:
- • 1. Must self-report concerns about enhanced risk of sexual offending against children
- • 2. Must be deemed to have capacity to provide informed consent;
- • 3. Must check the appropriate box on the informed consent form;
- • 4. Stated willingness to comply with all study procedures;
- • 5. Be 18 years of age or older upon study commencement.
- • For the benchmarking survey arm, participants must check the appropriate box on the informed consent form.
- EXCLUSION CRITERIA:
- For the treatment arms:
- • 1. Inability to engage meaningfully in group psychotherapy (e.g., due to intellectual disability, other neurodiversity, active psychosis or substance use)
- • 2. Those who self-identify as at-risk for reasons better accounted for by non-risk-relevant factors per clinical assessment (e.g., those with obsessive-compulsive disorder including thoughts about CSA, who commonly fear that they are at-risk but are not).
- • 3. Non-male sex.
- For the benchmarking interview arm:
- • 1. Non-male sex.
About Centre For Addiction And Mental Health
The Centre for Addiction and Mental Health (CAMH) is Canada’s leading mental health and addiction teaching hospital, dedicated to advancing research, clinical care, and education in the field of mental health. With a commitment to improving the lives of individuals affected by mental illness and addiction, CAMH conducts innovative clinical trials aimed at developing and evaluating new treatment approaches. The institution fosters a collaborative environment that brings together researchers, clinicians, and community partners to translate scientific findings into effective interventions, ensuring the highest standards of care and support for patients. Through its robust research initiatives, CAMH strives to enhance understanding of mental health disorders and promote evidence-based practices in the treatment of addiction and mental health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Artemis Igoumenou, M.D., Ph.D.
Principal Investigator
Complex Care and Recovery Program, Centre for Addiction and Mental Health (CAMH)
Ian McPhail, Ph.D., C. Psych.
Principal Investigator
Bloomberg School of Public Health, Johns Hopkins University
Cory Gerritsen, Ph.D., C. Psych
Principal Investigator
Slaight Centre for Early Intervention, Centre for Addiction and Mental Health (CAMH)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported